News | Artificial Intelligence | August 10, 2023

Blackford and AI4MedImaging Announce Partnership to enhance AI solutions offering for Cardiac MRI

Partnership makes AI4MedImaging’s AI4CMR solution available on the Blackford Platform 

Partnership makes AI4MedImaging’s AI4CMR solution available on the Blackford Platform

August 10, 2023 — Blackford, the pioneering strategic imaging AI platform and solutions provider, and AI4MedImaging, a cardiac MRI solution provider announce a partnership to make the AI4CMR solution available on the Blackford Platform. AI4CMR will enable Blackford customers to automatically segment and quantify cardiac MRI measurements. 

"Blackford’s mission is to deliver AI that provides value to healthcare providers to increase efficiency and improves patient outcomes,” said Blackford CEO Ben Panter. “We are excited to increase our cardiac MRI solution offering on the Blackford Platform with AI4MedImaging.” 

AI4CMR uses artificial intelligence to calculate, quantify, and analyse the left and right ventricle within 2 minutes, and produces a structured report to be extracted to any reporting system. It also provides a triage functionality for wall motion detection (this functionality is CE marked and FDA-pending). 

“AI4MedImaging is thrilled to partner with Blackford and contribute to the democratization of Cardiac Magnetic Resonance. With AI4CMR, the first cardiac AI to receive CE and FDA approval, analysis is fast, accurate, made-easy and available at any location due to the web-based cloud technology used,” said AI4MedImaging’s CEO and MD Vítor Pereira. 

For more information: www.blackfordanalysis.com


Related Content

News | FDA

Nov. 22, 2024 — BridgeBio Pharma, Inc. recently announced that the U.S. Food and Drug Administration (FDA) approved ...

Home November 25, 2024
Home
News | FDA

July 29, 2024 — CorVascular, a leading producer of peripheral arterial disease (PAD) / peripheral vascular disease (PVD) ...

Home July 29, 2024
Home
News | FDA

July 2, 2024 — The U.S. Food and Drug Administration (FDA) announced that Abbott has issued a correction for its ...

Home July 02, 2024
Home
News | FDA

June 18, 2024 — Elixir Medical has announced the company’s novel bioadaptive implant, DynamX Sirolimus-Eluting Coronary ...

Home June 18, 2024
Home
News | FDA

June 17, 2024 — Elutia Inc., a pioneer in drug-eluting biomatrix products, today announced that its Antibiotic-Eluting ...

Home June 17, 2024
Home
News | FDA

June 13, 2024 — Xeltis, a leading developer of transformative implants that enable the natural creation of living and ...

Home June 13, 2024
Home
News | FDA

June 3, 2024 — Heuron, a specialized medical AI startup focused on brain and neurological disorders based in South Korea ...

Home June 03, 2024
Home
News | FDA

May 17, 2024 — Implicity, a leader in remote patient monitoring and cardiac data management solutions, announced it has ...

Home May 17, 2024
Home
News | FDA

May 15, 2024 — The U.S. Food and Drug Administration (FDA) announced that Abbott is recalling the HeartMate 3 LVAS by ...

Home May 15, 2024
Home
News | FDA

May 8, 2024 — The US Food and Drug Administration (FDA) is alerting health care providers and facilities about our ...

Home May 08, 2024
Home
Subscribe Now